Scandion Oncology – Interim Report Q1 2023
Scandion Oncology (Scandion) today announces its interim report for Q1 2023. The following is taken from the report. Francois Martelet, CEO: “As our strong momentum continues, we have begun executing the first steps of our strategy to expand into Acute Myeloid Leukemia (AML)” Key Figures & Highlights TDKK Q1 2023 Q1 2022 FY 2022 Operating loss -11,974 -16,312 -80,166 Net finance income/cost 66 -251 -2,034 Loss before tax -11,908 -16,563 -82,200 Net loss -9,288 -12,919 -76,700 Total assets 73,873 101,259 89,401 Cash Position 60,185 87,965 77,605 Total equity 61,038 91,672 70,327 Equity ratio 83% 91% 79% Earnings per share (EPS) -0.23 -0.40 -1.88 Shares outstanding, ending 40,706,972 32,135,544 40,706,972 Highlights during Q1 2023 On January 18, Scandion appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management. Jan is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research. On January 19, Scandion receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101. The patent would provide protection of the commercial solid form of SCO-101 until at least 2042. On March 31, Scandion successfully completed the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial). The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Highlights after the end of the period On April 26 Scandion announced results of the Annual General Meeting. The interim report Q1 2023 is available on the Company's website: www.scandiononcology.com. Audiocast today, May 26 at 10:00 am CET Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be obtained as follows: LIVE access on Friday May 26, 2023, at 10:00 CET: https://financialhearings.com/event/46154 REPLAY accessWebcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on May 26, 2023, at 08.30 CET. Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront […]